We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study.
Pediatrics 1999 October
There are few historical data on final or adult heights after the completion of long-term growth hormone (GH) therapy in children with GH deficiency (GHD). Adult height has been defined as that achieved at chronologic ages ranging from 18 to 30 years, at bone ages >/=13 years (girls) and >/=15 years (boys), at growth velocities </=1 to 2 cm per 6 to 12 months, at the "cessation of growth," at "1 year after the completion of pubertal development," and that at which patients are either "satisfied with their height" or have attained an "accept adult stature." Without GH treatment, children with GHD have a mean adult height standard deviation score of -4.7 (range, -6. 1 to -3.9). After treatment, the standard deviation score range from -4.7 to -1.2 (pituitary GH [pitGH] 2-4 times a week) and from -1.4 to -0.5 (recombinant human [rhGH] GH 3 times a week to daily) in women and from -3.6 to -1.1 (pitGH) and from -1.3 to -0.7 (rhGH) in men. Because there is no uniformly applied definition of adult height, comparisons are difficult, but historical data suggest that posttreatment heights are greater with rhGH than with pitGH. Using the National Cooperative Growth Study database, we found that the criteria used to define adult height affected the apparent outcome. When chronologic age >/=20 years for men and >/=18 years for women was the only criterion, 27% of patients grew >/=5 cm after having reached this age. Adding the requirement of advanced puberty before adult height could be considered to have been attained reduced the proportion of those who later grew >/=5 cm to <10%, but also decreased the number of patients available for analysis. A combination of criteria for adult height (chronologic and bone age >/=16 years for boys and >/=14 years for girls plus advanced puberty plus growth rate of <2 cm per year) left only 1% of patients with later growth of >/=5 cm.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app